MXPA99001958A - Tableta con liberacion controlada de clorhidrato de alfuzosina. - Google Patents

Tableta con liberacion controlada de clorhidrato de alfuzosina.

Info

Publication number
MXPA99001958A
MXPA99001958A MXPA99001958A MX9901958A MXPA99001958A MX PA99001958 A MXPA99001958 A MX PA99001958A MX PA99001958 A MXPA99001958 A MX PA99001958A MX 9901958 A MX9901958 A MX 9901958A MX PA99001958 A MXPA99001958 A MX PA99001958A
Authority
MX
Mexico
Prior art keywords
layer
alfuzosine
hydrophilic polymers
release
controlled release
Prior art date
Application number
MXPA99001958A
Other languages
English (en)
Inventor
Rauch-Desanti Clemence
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA99001958(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MXPA99001958A publication Critical patent/MXPA99001958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Tableta farmaceutica para administracion oral para la liberacion controlada de clorhidrato de alfuzosina dentro de los segmentos proximos del tracto gastrointestinal, esta tableta que esta caracterizada en que consiste en: a) una primera capa 1 que tiene la propiedad de expandirse considerable y rapidamente al contacto con fluidos biologicos acuosos, dicha capa que se produce mediante compresion de una mezcla o de un granulado que comprende polimeros hidrofilicos que constituyen desde 5.0 hasta 90% y de preferencia desde 10 hasta 85% del peso de la capa. b) una segunda capa 2 adyacente a la primera capa, en la que se transporta el clorhidrato de alfuzosina, esta capa que esta formulada con polimeros hidrofilicos y con otras sustancias auxiliares, a fin de dar las propiedades de preparacion adecuadas de la capacidad de compresion y a fin de permitir la liberacion de clorhidrato de alfuzosina denso de un periodo predeterminado. c) y opcionalmente una tercera capa 3 obtenida mediante compresion y aplicada a la capa 2, que consta generalmente de polimeros hidrofilicos que forman gel y/o se expanden y que pueden opcionalmente separarse y que tienen funcion de barrera que modifica la liberacion del clorhidrato de alfuzosina desde la capa 2, la capa 3 que es en primer lugar altamente impermeable al paso de la sustancia activa.
MXPA99001958A 1996-08-29 1997-08-22 Tableta con liberacion controlada de clorhidrato de alfuzosina. MXPA99001958A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (1)

Publication Number Publication Date
MXPA99001958A true MXPA99001958A (es) 2005-09-08

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99001958A MXPA99001958A (es) 1996-08-29 1997-08-22 Tableta con liberacion controlada de clorhidrato de alfuzosina.

Country Status (37)

Country Link
US (1) US6149940A (es)
EP (1) EP0938318B1 (es)
JP (1) JP3797388B2 (es)
KR (1) KR100364328B1 (es)
CN (2) CN100335057C (es)
AP (1) AP1107A (es)
AR (1) AR009312A1 (es)
AT (1) ATE200864T1 (es)
AU (1) AU724490B2 (es)
BG (1) BG63768B1 (es)
BR (1) BR9713237B1 (es)
CA (1) CA2264250C (es)
CO (1) CO4920217A1 (es)
CY (1) CY2284B1 (es)
CZ (1) CZ295066B6 (es)
DE (1) DE69704712T2 (es)
DK (1) DK0938318T3 (es)
EE (1) EE03855B1 (es)
ES (1) ES2159400T3 (es)
GR (1) GR3036291T3 (es)
HK (1) HK1020875A1 (es)
HU (1) HU228007B1 (es)
IL (1) IL128146A (es)
IS (1) IS2091B (es)
MX (1) MXPA99001958A (es)
NO (1) NO326206B1 (es)
NZ (1) NZ334018A (es)
OA (1) OA10983A (es)
PL (1) PL191546B1 (es)
PT (1) PT938318E (es)
RU (1) RU2183459C2 (es)
SI (1) SI0938318T1 (es)
SK (1) SK284388B6 (es)
TR (1) TR199900289T2 (es)
TW (1) TW522023B (es)
UA (1) UA69374C2 (es)
WO (1) WO1998008515A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
ATE340563T1 (de) * 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
WO2004037228A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Sustained release compositions containing alfuzosin
JP2008508227A (ja) * 2004-07-29 2008-03-21 サノフイ−アベンテイス 高ｐｈ依存性溶解度を有する有効成分の放出制御のための医薬品多層錠剤
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
JP5296531B2 (ja) 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
EP1976488A4 (en) * 2006-01-12 2010-02-10 Wockhardt Ltd ALFUZOSIN PROLONGED RELEASE PREPARATIONS
JP2009544338A (ja) 2006-05-02 2009-12-17 プロテウス バイオメディカル インコーポレイテッド 患者に合わせてカスタマイズした治療レジメン
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
WO2008041553A1 (fr) 2006-09-26 2008-04-10 Astellas Pharma Inc. Préparation à libération entretenue de tacrolimus
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
EP2083680B1 (en) 2006-10-25 2016-08-10 Proteus Digital Health, Inc. Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
ES2930588T3 (es) 2007-02-01 2022-12-19 Otsuka Pharma Co Ltd Sistemas de marcador de eventos ingeribles
KR101528748B1 (ko) 2007-02-14 2015-06-15 프로테우스 디지털 헬스, 인코포레이티드 고 표면적 전극을 갖는 체내 전원
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
EP2124725A1 (en) 2007-03-09 2009-12-02 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
FI2192946T3 (fi) 2007-09-25 2022-11-30 Elimistön sisäinen laite, jossa on virtuaalinen dipolisignaalinvahvistus
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2009221781B2 (en) 2008-03-05 2014-12-11 Otsuka Pharmaceutical Co., Ltd. Multi-mode communication ingestible event markers and systems, and methods of using the same
CN102131488A (zh) * 2008-06-04 2011-07-20 宝洁公司 义齿粘合剂组合物和方法
MY154234A (en) 2008-07-08 2015-05-15 Proteus Digital Health Inc Ingestible event marker data framework
AU2009281876B2 (en) 2008-08-13 2014-05-22 Proteus Digital Health, Inc. Ingestible circuitry
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
WO2013012869A1 (en) 2011-07-21 2013-01-24 Proteus Digital Health, Inc. Mobile communication device, system, and method
JP2012514799A (ja) 2009-01-06 2012-06-28 プロテウス バイオメディカル インコーポレイテッド 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
EP3395333A1 (en) 2009-01-06 2018-10-31 Proteus Digital Health, Inc. Pharmaceutical dosages delivery system
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2010111403A2 (en) 2009-03-25 2010-09-30 Proteus Biomedical, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
CN102458236B (zh) 2009-04-28 2016-01-27 普罗秋斯数字健康公司 高可靠性的可摄入事件标记器及其使用方法
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
JP5730915B2 (ja) 2010-03-10 2015-06-10 ザ プロクター アンド ギャンブルカンパニー 義歯接着剤組成物
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
BR112012025650A2 (pt) 2010-04-07 2020-08-18 Proteus Digital Health, Inc. dispositivo ingerível miniatura
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
SG11201503027SA (en) 2012-10-18 2015-05-28 Proteus Digital Health Inc Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
JP2016508529A (ja) * 2013-01-29 2016-03-22 プロテウス デジタル ヘルス， インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
KR102051875B1 (ko) 2016-07-22 2019-12-04 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 이벤트 마커의 전자기 감지 및 검출
EP3531901A4 (en) 2016-10-26 2021-01-27 Proteus Digital Health, Inc. CAPSULE PREPARATION PROCESSES WITH INGERABLE EVENT MARKERS
CN114209668B (zh) * 2022-01-13 2023-01-31 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
NZ334018A (en) 1999-06-29
CZ295066B6 (cs) 2005-05-18
US6149940A (en) 2000-11-21
EP0938318B1 (fr) 2001-05-02
PL191546B1 (pl) 2006-06-30
CY2284B1 (en) 2003-07-04
RU2183459C2 (ru) 2002-06-20
CA2264250A1 (en) 1998-03-05
HUP9903428A3 (en) 2000-04-28
NO990944D0 (no) 1999-02-26
GR3036291T3 (en) 2001-10-31
IS2091B (is) 2006-03-15
PL331862A1 (en) 1999-08-16
BG103138A (en) 1999-09-30
CZ65599A3 (cs) 1999-06-16
HU228007B1 (en) 2012-08-28
UA69374C2 (uk) 2004-09-15
SI0938318T1 (en) 2001-12-31
CA2264250C (en) 2005-07-05
ATE200864T1 (de) 2001-05-15
AP1107A (en) 2002-09-20
HK1020875A1 (en) 2000-05-26
WO1998008515A1 (fr) 1998-03-05
IL128146A (en) 2001-01-11
DE69704712T2 (de) 2001-11-29
TW522023B (en) 2003-03-01
EP0938318A1 (fr) 1999-09-01
JP2000514462A (ja) 2000-10-31
CN100335057C (zh) 2007-09-05
CN1228700A (zh) 1999-09-15
JP3797388B2 (ja) 2006-07-19
ES2159400T3 (es) 2001-10-01
KR100364328B1 (ko) 2002-12-26
HUP9903428A2 (hu) 2000-02-28
AU4020197A (en) 1998-03-19
CN1543954A (zh) 2004-11-10
BR9713237A (pt) 2000-04-04
AR009312A1 (es) 2000-04-12
CO4920217A1 (es) 2000-05-29
SK284388B6 (sk) 2005-02-04
EE03855B1 (et) 2002-10-15
BR9713237B1 (pt) 2009-01-13
BG63768B1 (bg) 2002-12-29
IL128146A0 (en) 1999-11-30
TR199900289T2 (xx) 2000-12-21
SK27099A3 (en) 1999-12-10
DK0938318T3 (da) 2001-08-20
EE9900090A (et) 1999-10-15
PT938318E (pt) 2001-10-30
KR20000035929A (ko) 2000-06-26
NO990944L (no) 1999-04-27
AP9901470A0 (en) 1999-03-31
OA10983A (fr) 2003-03-04
NO326206B1 (no) 2008-10-20
IS4964A (is) 1999-01-29
AU724490B2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
MXPA99001958A (es) Tableta con liberacion controlada de clorhidrato de alfuzosina.
Nagar et al. Orally disintegrating tablets: formulation, preparation techniques and evaluation
US5651985A (en) Expandable pharmaceutical forms
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
AU727753B2 (en) Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
NO178095C (no) Fremgangsmåte for fremstilling av et omhyllet farmasöytisk retarderingspreparat
JP2018522817A (ja) 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
ATE267007T1 (de) Pharmazeutische tablette geeignet zur wirkstofffreisetzung in aufeinanderfolgenden und vorherbestimmbaren zeiträumen
CA2130487A1 (en) Fast soluble tablet
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
WO2005007139A3 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
DE69521688T2 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
AR036838A1 (es) Comprimido de varias capas de liberacion controlada, uso del mismo para la fabricacion de un medicamento util en el tratamiento de la fibromialgia y composicion farmaceutica que lo comprende.
JPH05502894A (ja) 放出制御性製剤及び方法
WO2001039752A3 (de) Transdermales therapeutisches system enthaltend leicht flüchtige wirkstoffe
NO320050B1 (no) Transmukosale formuleringer av levosimendan og anvendelse derav til fremstilling av faramasoytisk preparat.
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
FI118952B (fi) Hidastetusti mahanportin läpi kulkeutuva vaikuttavien aineiden kantaja vaikuttavien aineiden vapauttamiseksi säädellysti ruoansulatuskanavassa
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
WO2004037226B1 (en) Pharmaceutical compositions containing venlafaxine
IT1318470B1 (it) Matrici polimeriche idrofile/lipofile, in grado di cedere sostanzefarmacologiamente attive a velocita' predeterminata.

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration